Standout Papers

Non-pathogenic Escherichia coli versus mesalazine for the treatment of ulcerative colitis: a r... 1999 2026 2008 2017 786
  1. Non-pathogenic Escherichia coli versus mesalazine for the treatment of ulcerative colitis: a randomised trial (1999)
    A.M. Snelling, D M Chalmers et al. The Lancet

Immediate Impact

3 by Nobel laureates 43 from Science/Nature 73 standout
Sub-graph 1 of 21

Citing Papers

The microbiome and human cancer
2021 StandoutScience
Metabolic modulation of tumours with engineered bacteria for immunotherapy
2021 StandoutNature
2 intermediate papers

Works of ATR Axon being referenced

Non-pathogenic Escherichia coli versus mesalazine for the treatment of ulcerative colitis: a randomised trial
1999 Standout

Author Peers

Author Last Decade Papers Cites
ATR Axon 416 143 414 484 9 1.4k
Adrianus C. J. M. de Bruijn 156 169 373 805 12 1.5k
Steven L. Brandwein 353 226 337 334 14 1.6k
Marianne Ortner 168 256 489 663 11 1.5k
Jun Yu 293 190 125 942 10 1.4k
Eva Martini 244 213 374 985 16 1.7k
Karolina S. Jabbar 142 157 291 840 10 1.3k
Kathryn Lynch–Devaney 163 83 218 598 9 1.5k
Mitsutoshi Iimura 181 225 417 541 12 1.7k
Lisa Dreolini 484 178 121 1158 10 1.6k
Rachael J. Rigby 253 306 396 629 23 1.7k

All Works

Loading papers...

Rankless by CCL
2026